N = 1, Fortuitous Effects, And AIDS Research

A recent article on xenotransplantation (R. Finn, The Scientist, Aug. 19, 1996, page 1) and two responses to my commentary (M. Jasienski, The Scientist, March 4, 1996, page 10), which was critical of a single-subject baboon bone-marrow transplant trial, prompt me to explicate some methodological issues further. What insights can a single-subject study provide? While, as pointed out by J.E. Janosky (The Scientist, May 27, 1996, page 12), there could be some room for N = 1 studies, J.G. Llaurado

Written byMichal Jasienski
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

A recent article on xenotransplantation (R. Finn, The Scientist, Aug. 19, 1996, page 1) and two responses to my commentary (M. Jasienski, The Scientist, March 4, 1996, page 10), which was critical of a single-subject baboon bone-marrow transplant trial, prompt me to explicate some methodological issues further. What insights can a single-subject study provide? While, as pointed out by J.E. Janosky (The Scientist, May 27, 1996, page 12), there could be some room for N = 1 studies, J.G. Llaurado unintentionally strengthens my skepticism in this matter (The Scientist, July 8, 1996, page 12). Llaurado writes that the currents that Alessandro Volta used on himself to study electricity are "today believed sufficient to cause lethal arrhythmias on a less corpulent man than Volta." Is it then not quite fortunate for the development of science that Volta was overweight (that is, not representative of the whole population)? How many Voltas were ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies